Evidence map›Paper›PMID 31498563›Full record

ArticleJournal of the International AIDS Society2019

Perinatal outcomes following maternal pre-exposure prophylaxis (PrEP) use during pregnancy: results from a large PrEP implementation program in Kenya.

Julia C Dettinger, John Kinuthia, Jillian Pintye, Felix Abuna, Emily Begnel, Kenneth Mugwanya, Joseph Sila, Harison Lagat, Jared M Baeten, Grace John-Stewart

Registry-linked trialAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06022809 (Comparative Effectiveness of Individual Versus Group-level Interventions to Reduce HIV Risk Among African Immigrant Women), which is not on this map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06022809 nacompletednot on this mapstarted 2023, after this paper: background citation

Comparative Effectiveness of Individual Versus Group-level Interventions to Reduce HIV Risk Among African Immigrant Women

TypeinterventionalSponsorMassachusetts General HospitalRan2023 to 2026Enrolled149ConditionsHIV, Other STIsArmsDada Kwa Dada (individual-level), DADA (group-level)
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Frontiers in pediatrics · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Julia C DettingerDepartment of Global Health, University of Washington, Seattle, WA, USA.ORCID 0000-0002-9130-2666
John KinuthiaDepartment of Global Health, University of Washington, Seattle, WA, USA.ORCID 0000-0001-6571-8927
Jillian PintyeDepartment of Global Health, University of Washington, Seattle, WA, USA.
Felix AbunaUniversity of Washington - Kenya, Nairobi, Kenya.
Emily BegnelDepartment of Global Health, University of Washington, Seattle, WA, USA.
Kenneth MugwanyaDepartment of Global Health, University of Washington, Seattle, WA, USA.
Joseph SilaUniversity of Washington - Kenya, Nairobi, Kenya.
Harison LagatUniversity of Washington - Kenya, Nairobi, Kenya.
Jared M BaetenDepartment of Global Health, University of Washington, Seattle, WA, USA.ORCID 0000-0001-8242-8438
Grace John-StewartDepartment of Global Health, University of Washington, Seattle, WA, USA.

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI EDWIN ROBERTO ORELLANA · 1988 to 2026
$104.9M
Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
NCCIH Supplement to NCATS/CTSA Program for KL2 Scholars - M. SoddersKL2TR002317 · NCATS · UNIVERSITY OF WASHINGTON · PI Christy Michelle McKinney · 2017 to 2026
$14.5M
NRSA Training CoreTL1TR002318 · NCATS · UNIVERSITY OF WASHINGTON · PI Megan Moore · 2017 to 2026
$8.4M
A differentiated care model to improve the efficiency of PrEP delivery in KenyaR00MH118134 · NIMH · UNIVERSITY OF WASHINGTON · PI MUGWANYA, KENNETH KIGGUNDU · 2019 to 2021
$743k
A differentiated care model to improve the efficiency of PrEP delivery in KenyaK99MH118134 · NIMH · UNIVERSITY OF WASHINGTON · PI MUGWANYA, KENNETH KIGGUNDU · 2018 to 2018
$123k
Adherence to Pre-Exposure Prophylaxis for HIV Prevention in PregnancyF32NR017125 · NINR · UNIVERSITY OF WASHINGTON · PI PINTYE, JILLIAN · 2017 to 2017
$61k
NCATS NIH HHS KL2 TR002317NCATS NIH HHS TL1 TR002318NCATS NIH HHS UL1 TR002319NIAID NIH HHS P30 AI027757NIMH NIH HHS K99 MH118134NIMH NIH HHS R00 MH118134NINR NIH HHS F32 NR017125
6 · The paper itself

Abstract

introductionThe World Health Organization, while recommending pre-exposure prophylaxis (PrEP) for HIV-negative pregnant and postpartum women in HIV high-burden settings, advocates for continued safety evaluation of PrEP in this population.

methodsThe PrEP Implementation in Young Women and Adolescents (PrIYA) program delivered PrEP to pregnant and postpartum women integrated within routine maternal and child health clinics (MCH) at 16 sites in Western Kenya. PrEP exposure and perinatal outcome data were collected among women obtaining postnatal services during programme evaluation. PrEP use was self-reported and confirmed with clinical records. Perinatal outcomes including gestational age at birth, birthweight, congenital malformations and infant growth outcomes were abstracted from clinical records for mother-infant pairs attending the six week visit. Associations between infant outcomes and maternal prenatal PrEP use were assessed using univariate and multivariate logistic and linear regression.

resultsThe PrIYA evaluation identified 1530 postpartum mother-infant pairs with data on prenatal PrEP exposure: 206 with prenatal PrEP use, 1324 without. Median maternal age was 24 years in both groups. PrEP users (any reported PrEP use) were significantly more likely to report HIV risk factors such as: intimate partner violence, sexually transmitted infections and having a partner with positive or unknown HIV status. Most mothers initiated PrEP during the second trimester (n = 116, 57%) and used PrEP for more than one month (n = 110, 58%). The mean birthweight was 3.3 kg and gestational age at birth was 38.5 weeks in both groups. There were no major differences between PrEP exposed and unexposed infants in rates of preterm birth and low birthweight. There were no congenital malformations identified in the PrEP-exposed group and five reported in the PrEP unexposed group. At six weeks postpartum, infants in both groups had similar growth. No differences in infant outcomes were found by duration PrEP exposure, trimester of PrEP initiation, a subset analysis of women 15 to 24 years old or in multivariate analyses. This analysis demonstrates that monitoring of infant outcomes is feasible within large-scale programmatic implementation of PrEP among pregnant and postpartum populations.

conclusionsPregnancy outcomes and early infant growth did not differ by PrEP exposure.

Indexed as

AdolescentAdultAnti-HIV AgentsBirth WeightFemaleHIV InfectionsHumansInfantInfant, NewbornInfectious Disease Transmission, VerticalKenyaMaternal ExposurePre-Exposure ProphylaxisPregnancyPregnancy Complications, InfectiousPregnancy OutcomeAnti-HIV AgentsAfricachildreninfantpre-exposure prophylaxispregnancypreventionwomen

Identifiers

PMID31498563
PMCPMC6733245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.